Previous research has revealed that ARID1A mutation or ARID1A expression loss contributes to the dMMR subtype, higher PD-L1 expression and remodeling of the TIME, which leads to enhanced sensitivity to ICIs in ovarian cancer [31] and gastric cancer [32]. The gene discussed is ARID1A; the disease is gastric cancer.